<DOC>
	<DOCNO>NCT03042416</DOCNO>
	<brief_summary>Single centre prospective cohort phase III study 18F-DOPA PET/CT image specific patient population : 1 . Pediatric patient congenital hyperinsulinism 2 . Pediatric patient neuroblastoma 3 . Pediatric Adult patient suspect extra-pancreatic neuroendocrine tumor 4 . Adult patient clinical suspicion Parkinson 's disease 5 . Pediatric Adult patient primary brain tumor This study evaluate biodistribution safety 18F-DOPA produced Edmonton PET Centre .</brief_summary>
	<brief_title>18F-DOPA PET Imaging : Evaluation Biodistribution Safety</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Hyperinsulinism</mesh_term>
	<mesh_term>Congenital Hyperinsulinism</mesh_term>
	<mesh_term>Dihydroxyphenylalanine</mesh_term>
	<criteria>1 . Pediatric patient ( less 17 year old ) congenital hyperinsulinism 2 . Pediatric patient ( less 17 year old ) neuroblastoma 3 . Pediatric patient ( less 17 year old ) Adult patient ( 17 old ) know clinically suspect neuroendocrine tumor outside pancreas 4 . Adult patient ( 17 old ) clinical suspicion Parkinson 's disease . 5 . Pediatric ( less 17 year old ) Adult patient ( 17 old ) primary brain tumor Unable obtain consent Weight &gt; 250 kg ( weight limitation PET/CT scanner ) Adult patient unable lie flat 2030 minute complete PET/CT scan Young pediatric patient ( less 10 year old ) unable lie flat 2030 minute clinical sedation contraindicate ( determine pediatric anaesthesiologist ) Pregnancy Lack intravenous access</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>18F-DOPA PET/CT</keyword>
</DOC>